JP2012519484A5 - - Google Patents

Download PDF

Info

Publication number
JP2012519484A5
JP2012519484A5 JP2011552950A JP2011552950A JP2012519484A5 JP 2012519484 A5 JP2012519484 A5 JP 2012519484A5 JP 2011552950 A JP2011552950 A JP 2011552950A JP 2011552950 A JP2011552950 A JP 2011552950A JP 2012519484 A5 JP2012519484 A5 JP 2012519484A5
Authority
JP
Japan
Prior art keywords
mir
sequence
seq
mre
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011552950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519484A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/000709 external-priority patent/WO2010101663A2/en
Publication of JP2012519484A publication Critical patent/JP2012519484A/ja
Publication of JP2012519484A5 publication Critical patent/JP2012519484A5/ja
Pending legal-status Critical Current

Links

JP2011552950A 2009-03-06 2010-03-08 マイクロrna応答要素を含む弱毒化生インフルエンザウイルスワクチン Pending JP2012519484A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15823309P 2009-03-06 2009-03-06
US61/158,233 2009-03-06
PCT/US2010/000709 WO2010101663A2 (en) 2009-03-06 2010-03-08 Live attenuated influenza virus vaccines comprising microrna response elements

Publications (2)

Publication Number Publication Date
JP2012519484A JP2012519484A (ja) 2012-08-30
JP2012519484A5 true JP2012519484A5 (https=) 2013-04-25

Family

ID=42710158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011552950A Pending JP2012519484A (ja) 2009-03-06 2010-03-08 マイクロrna応答要素を含む弱毒化生インフルエンザウイルスワクチン

Country Status (5)

Country Link
US (1) US8883995B2 (https=)
EP (1) EP2403527A4 (https=)
JP (1) JP2012519484A (https=)
CA (1) CA2754826A1 (https=)
WO (1) WO2010101663A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523672C (en) 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CA2721366C (en) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation of an immune response by enantiomers of cationic lipids
US8883995B2 (en) * 2009-03-06 2014-11-11 Icahn School Of Medicine At Mount Sinai Live attenuated influenza virus vaccines comprising microRNA response elements
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011131193A1 (en) * 2010-04-24 2011-10-27 Statens Serum Institut Diagnosing and treating fibrotic diseases using micro-rna 17
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
CN103648491B (zh) * 2011-04-08 2017-07-14 法国国家健康医学研究院 用于抑制流感病毒复制的方法和药物组合物
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US20130280215A1 (en) * 2011-10-18 2013-10-24 Geovax, Inc. Mva vectors expressing polypeptides and having high level production in certain cell lines
EP3536789A1 (en) * 2012-06-06 2019-09-11 Boehringer Ingelheim International GmbH Cell engineering using rnas
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
JP6483033B2 (ja) 2013-03-05 2019-03-13 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティOregon Health & Science University T細胞ターゲティングを調節することができるサイトメガロウイルスベクター
CN105101995A (zh) * 2013-03-15 2015-11-25 宾夕法尼亚大学理事会 具有生物分子佐剂的疫苗
CN104694541A (zh) 2013-12-09 2015-06-10 江苏命码生物科技有限公司 禽流感病毒miRNA及其鉴定、检测和应用
US20170130229A1 (en) * 2014-06-18 2017-05-11 The Regents Of The University Of California Methods and compositions for inhibiting infection by influenza and viruses
KR102403547B1 (ko) 2014-07-16 2022-05-30 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
WO2016061200A1 (en) * 2014-10-14 2016-04-21 Texas Tech University System Live attenuated viral vaccine created by self-attenuation with species-specific artificial microrna
JP6620294B2 (ja) * 2014-12-03 2019-12-18 公益財団法人ヒューマンサイエンス振興財団 ムンプスウイルスの弱毒化方法、ムンプスウイルス、及び、生ワクチン
JP6816031B2 (ja) 2015-02-10 2021-01-20 オレゴン ヘルス アンド サイエンス ユニバーシティ 非標準的なcd8+t細胞応答を生成するのに有用な方法および組成物
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
WO2016201127A1 (en) * 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US10086063B2 (en) 2015-09-23 2018-10-02 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
US10383935B2 (en) 2015-09-23 2019-08-20 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
AU2016355468B2 (en) * 2015-11-20 2022-12-15 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
WO2018007575A1 (en) * 2016-07-08 2018-01-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Genomic sequences encoding for an attenuated mutant zika virus
CN110036112B (zh) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CA3084957A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
JP2021508696A (ja) 2017-12-22 2021-03-11 コーダ−ジェニックス・インコーポレイテッドCoda−Genix, Inc. がん処置のためのコドン対脱最適化領域を有する組換え型ウイルス及びその使用法
CN112040977A (zh) 2018-03-08 2020-12-04 科达金尼克斯有限公司 减毒黄病毒
WO2019204571A1 (en) 2018-04-20 2019-10-24 Texas Tech University System Self-attenuated prophylactic and therapeutic vaccines against pathogens
WO2020244605A1 (zh) * 2019-06-04 2020-12-10 凌斌 重组非结构蛋白1、含此的重组流感病毒及免疫组成物及其用于制备流感病毒疫苗组成物的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1567007B1 (en) 2002-11-13 2012-02-22 Thomas Jefferson University Compositions and methods for cancer diagnosis and therapy
NZ542935A (en) * 2003-04-23 2008-08-29 Wisconsin Alumni Res Found Recombinant influenza viruses holding a mutation in a transmembrane protein gene
WO2005017111A2 (en) * 2003-07-15 2005-02-24 The Trustees Of The University Of Pennsylvania Methods and systems for identifying micro-rna targets and synthesizing novel micro-rnas and uses of the same
US8106180B2 (en) * 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US7279275B2 (en) 2003-11-03 2007-10-09 Washington University Methods and compositions for detection of segmented negative strand RNA viruses
WO2006033691A2 (en) 2004-07-02 2006-03-30 Niman Henry L Copy choice recombination and uses thereof
US20070213293A1 (en) * 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
US20070054872A1 (en) * 2005-08-24 2007-03-08 Mirus Bio Corporation Regulatable or conditional expression systems
US20080045472A1 (en) * 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
US9072701B2 (en) 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
EP2099903A4 (en) * 2006-12-22 2010-07-28 Penn State Res Found MODIFIED POLYMERASES AND WEIGHTENED VIRUSES AND METHOD FOR THEIR USE
WO2008103643A1 (en) 2007-02-20 2008-08-28 Monsanto Technology, Llc Invertebrate micrornas
EP4368202A3 (en) * 2007-03-30 2024-08-21 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
EP2183386A1 (en) * 2007-05-31 2010-05-12 Yale University A genetic lesion associated with cancer
WO2009079592A2 (en) * 2007-12-17 2009-06-25 California Institute Of Technology Modulating immune system development and function through microrna mir-146
WO2009111892A1 (en) * 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
US8883995B2 (en) * 2009-03-06 2014-11-11 Icahn School Of Medicine At Mount Sinai Live attenuated influenza virus vaccines comprising microRNA response elements

Similar Documents

Publication Publication Date Title
JP2012519484A5 (https=)
Menon et al. miRNA: a promising therapeutic target in cancer
Tenoever RNA viruses and the host microRNA machinery
HRP20190992T1 (hr) Suprimiranje gena za huntingtin inducirano s rnai
Drury et al. The clinical application of microRNAs in infectious disease
Booton et al. Emerging role of MicroRNAs and long noncoding RNAs in respiratory disease
JP2009519339A5 (https=)
JP5652830B2 (ja) マイクロrna制御組換えワクシニアウイルス及びその使用
Keshavarz et al. miRNA-based strategy for modulation of influenza A virus infection
Wei et al. MyD88 as a target of microRNA-203 in regulation of lipopolysaccharide or Bacille Calmette-Guerin induced inflammatory response of macrophage RAW264. 7 cells
ZA202003137B (en) Nucleic acid, composition and conjugate containing same, and preparation method and use
Zhang et al. Induction of the cellular miR-29c by influenza virus inhibits the innate immune response through protection of A20 mRNA
WO2013090457A3 (en) In vivo delivery of oligonucleotides
Bela-ong et al. Involvement of two microRNAs in the early immune response to DNA vaccination against a fish rhabdovirus
BR112017007923A2 (pt) método para produzir manipulação genética mediada por reações multiplex com rna em uma célula receptora, construção de ácido nucleico, cassete de expressão, vetor, célula receptora, célula geneticamente modificada, tecido, planta ou animal, progênie de planta ou animal e método para modificar um sítio alvo no genoma de uma célula
WO2013166264A2 (en) Methods for altering virus replication
Samir et al. MicroRNAs in the host response to viral infections of veterinary importance
Shi et al. Novel microRNA‐like viral small regulatory RNAs arising during human hepatitis A virus infection
CN104651364B (zh) 一种竞争性消耗致癌性microRNAs的LncRNA、溶瘤腺病毒及其用途
Ramadan et al. MicroRNA signatures in the pathogenesis and therapy of inflammatory bowel disease
Abo-Al-Ela The emerging regulatory roles of noncoding RNAs in immune function of fish: MicroRNAs versus long noncoding RNAs
Shirvani et al. RETRACTED: Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significance
JP2014516530A5 (https=)
CN101402945A (zh) 表达抗传染性法氏囊病病毒微小rna重组禽腺联病毒的制备方法
Li et al. Inhibition of influenza A virus replication by RNA interference targeted against the PB1 subunit of the RNA polymerase gene